The effect of regression of cirrhosis in chronic Hepatitis C is unknown.
Dr Vincent Mallet and colleagues from France evaluated the relation between regression of cirrhosis and clinical outcome in patients with chronic Hepatitis C after antiviral therapy.
The research team evaluated a cohort of patients with cirrhosis treated between 1988 and 2001, and followed until 2006.
The team treated 96 patients with chronic Hepatitis C and biopsy-proven cirrhosis with an interferon-based regimen and had at least 1 posttreatment liver biopsy.
The team evaluated occurrence of a combined end point of liver-related events and death in patients with regression of cirrhosis.
The researchers reported that the median follow-up was 118 months.
|The transplant-free survival rate at 10 years was 100% with regression of cirrhosis|
|Annals Internal Medicine|
The research team identified 18 patients that had regression of cirrhosis.
The incidence of the combined end point per 100 patient-years was 0 in patients with regression of cirrhosis, and 4 in patients without regression of cirrhosis.
The transplantation-free survival rate at 10 years was 100% in patients with regression of cirrhosis, and 74% in patients without regression of cirrhosis.
Selection of patients was retrospective, although selection and survival biases may have influenced the estimates of the overall rate of regression of cirrhosis.
The low number of patients who experienced regression of cirrhosis precludes analysis of factors that could predict regression of cirrhosis.
Dr Mallet’s team concluded, “Regression of cirrhosis occurs after antiviral therapy in some patients with chronic Hepatitis C.”
“Regression is associated with decreased disease-related morbidity and improved survival.”